Congress · Agencies · Public Funding
Federal Tracking
A careful, primary-source-first guide to federal developments affecting ibogaine and its analogues: bills, rules, regulatory records, and public funding.
A working record
Follow the federal record, not the noise.
Federal policy can move through several channels at once: legislation in Congress, executive action, agency rulemaking, drug-control proceedings, regulatory filings, and appropriations or grant activity. This page is an evergreen framework for distinguishing those records and for checking the original text before drawing conclusions.
For broader context on how policy choices shape access, oversight, and evidence development, begin with the independent ibogaine policy resource. Questions about this project’s methods and boundaries belong with Ivory Docket’s stated purpose and principles, rather than being inferred from a headline or a secondary summary.
Ibogaine is generally discussed in federal law through drug-control and regulatory frameworks. The DEA’s drug scheduling overview is a useful starting point for understanding the legal categories that may be relevant, but it is not a substitute for the actual statute, regulation, or notice at issue.
Where the evidence sits
Five federal channels worth separating.
Each channel has its own procedural record, vocabulary, and legal effect. A bill is not enacted law; a notice is not necessarily a final rule; a grant opportunity is not an award; and an agency document should not be treated as a clinical conclusion.
- CongressIntroduced bills, committee activity, enacted provisions, appropriations language, and Congressional Record entries.
- Executive actionExecutive orders, memoranda, and agency implementation materials that may set direction without changing statute.
- FDA materialsGuidance, advisory committee notices, briefing materials, and public information about investigational pathways.
- DEA actionScheduling notices, proposed or final rules, and related administrative documents.
- FundingGrant announcements, contracts, appropriations, and award records that may support research or implementation activity.
Source discipline
Use the record closest to the action.
For bills, start with official bill text and legislative status at Congress.gov, then compare the current version, sponsor, committee referral, actions, and any enacted text. For floor statements or debates, locate the relevant date and chamber in the Congressional Record rather than relying on paraphrase.
For proposed and final rules, search the Federal Register’s official notice archive. Read the agency, docket number, publication date, effective date, comment window, and whether the document is proposed, interim, final, corrected, or withdrawn.
For research support, check the current opportunity or award entry in the federal grants portal. Funding announcements, applications, awards, and completed work are different stages and should be labeled accordingly. The site’s research and policy-navigation materials can help readers keep those distinctions visible without turning a record search into an efficacy claim.
“Verification is not a formality: it is the line between a policy signal and an established federal action.”
2024–2026 review frame
A concise timeline for checking milestones.
This is a verification timeline, not a claim that a particular ibogaine measure advanced in every period. It identifies the records that should be rechecked as federal activity changes. Search by bill number, docket number, agency, program, and publication date; record the version and date you reviewed.
Where a federal action may intersect with drug classification, the Controlled Substances Act’s statutory framework offers high-level context, while the enacted U.S. Code and the specific agency document remain the sources to use for legal interpretation.
-
Establish a baseline
Check congressional databases, Federal Register notices, agency pages, and active funding announcements for the starting record. Save the date, document title, and stable citation for each item.
-
Compare proposal with action
Track whether introduced language changed through committee action, substitution, amendment, appropriation, withdrawal, or expiration. Confirm whether an agency matter remained proposed or became final.
-
Reconfirm before republication
Reopen the primary text before characterizing legal status, funding availability, or agency posture. Dates, implementation terms, and linked documents can change after an initial publication.
Editorial boundaries
What this tracker does—and does not—say.
Federal records can show that a proposal was introduced, a notice was published, a program was announced, or an agency process exists. They do not by themselves establish clinical efficacy, individual safety, treatment suitability, or legal advice for a particular person or organization.
FDA materials may refer to investigational work or regulatory process. The FDA’s overview of investigational new drug applications explains that an IND is a pathway for clinical investigation; it should not be represented as product approval or as a statement about outcomes.
Keep the record in view
Policy context deserves careful reading.
For a separate discussion of questions people may bring to ibogaine and depression, consult ibogaine and depression context; it should not be treated as a substitute for primary federal records, medical guidance, or legal counsel.